A total of 76 patients with advanced NSCLC with EGFR major mutations (del19 or L858R) receiving first-line osimertinib were eligible as the osimertinib (Osi) group, whereas 43 patients receiving first- or second-generation EGFR-TKIs were compared with the control group....Patients harboring L858R with coexpression of high VEGFR2 and VEGF-C displayed significantly worse PFS and OS than those with coexpression of low VEGFR2 and VEGF-C or lack of coexpression (Figure 3k,l), but not with del19 (Figure 3i,j).